Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report sent to investors on Thursday, MarketBeat reports. The brokerage currently has a $22.00 target price on the stock.

A number of other research firms have also weighed in on ACRV. LADENBURG THALM/SH SH raised shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Monday, September 16th. BMO Capital Markets reiterated an “outperform” rating and set a $28.00 price target (up from $25.00) on shares of Acrivon Therapeutics in a research report on Monday, September 16th. JMP Securities reissued a “market outperform” rating and set a $17.00 target price on shares of Acrivon Therapeutics in a research note on Monday, September 16th. Finally, Piper Sandler Companies reaffirmed a “buy” rating and set a $30.00 price target on shares of Acrivon Therapeutics in a report on Friday, September 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $6.96 on Thursday. Acrivon Therapeutics has a 12 month low of $3.19 and a 12 month high of $11.90. The company has a 50-day moving average of $7.78 and a 200-day moving average of $7.78. The company has a market cap of $215.57 million, a P/E ratio of -2.58 and a beta of 0.66.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of institutional investors have recently made changes to their positions in the business. American International Group Inc. boosted its stake in Acrivon Therapeutics by 39.2% during the first quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after buying an additional 1,695 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Acrivon Therapeutics during the second quarter worth approximately $58,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics in the 2nd quarter valued at $61,000. Rhumbline Advisers boosted its holdings in Acrivon Therapeutics by 48.9% in the second quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after acquiring an additional 5,320 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after buying an additional 11,273 shares during the period. 71.62% of the stock is currently owned by institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.